NSCLC, Stage IIIA
7 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations (NCT05157776) | Tongji University | 2021-10-28 |
| Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC (NCT04865250) | University Hospital Heidelberg | 2021-01-07 |
| Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer (NCT03628144) | H. Lee Moffitt Cancer Center and Research Institute | 2020-07-01 |
| Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients (NCT04205552) | University Hospital, Essen | 2020-03-04 |
| Metabolomics Predict Therapy Response (NCT03736993) | Hasselt University | 2018-05-28 |
| Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations (NCT01470716) | National Cancer Center, Korea | 2012-01-01 |
Track NSCLC, Stage IIIA automatically
Every clearance here is in the API, with alerts when new ones post.